LIDDS AB, Local Implant Drug Delivery System (LIDDS) is a privately-held life sciences company, engaged in developing innovative pharmaceutical products on the basis of its proprietary drug delivery technology. It offers a new product, namely, Liproca, for the treatment of prostate cancer. Liproca is a novel bioresorbable, biocompatible and locally implantable controlled release formulation of 2-hydroxyflutamide. Various advantages of this product includes, local administration would provide for an optimal concentration and clinical effect of the active pharmaceutical ingredient in the target organ while the systemic concentration remains low with no or very limited side-effects; reduced in vivo fluctuation of drug concentrations within the therapeutic interval, reduced dosing frequency and improved patient compliance, limited risk for specific drug-drug interactions, the ceramic material will also make it possible to increase the accuracy in dose-positioning since the injected material will be visible with ultrasound; potential for higher local tissue concentrations and thus better effect; significantly reduced liver and systemic drug concentrations and therefore a great potential for reduced hormone related adverse effect panorama. LIDDS is headquartered in Helsingborg, Sweden.